Literature DB >> 9416943

Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction.

J D Schlaifer1, T J Wargovich, B O'Neill, G B Mancini, H E Haber, B Pitt, C J Pepine.   

Abstract

This pilot study evaluates the effects of quinapril, an angiotensin-converting enzyme inhibitor with high tissue-binding affinity, on microvascular endothelial function in patients with mild (<40% narrowing) coronary artery disease and epicardial endothelial dysfunction. Patients randomized to quinapril had a trend suggesting an increase in endothelium-dependent coronary blood flow response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416943     DOI: 10.1016/s0002-9149(97)00750-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Stable Angina Pectoris.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 2.  [Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis].

Authors:  V Schächinger
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

3.  Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.

Authors:  Gul Yener; Sinan Aran; Mithat Bahceci; Kurtulus Ozdemir; Fusun Gultekin; Wing Lowe
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

4.  No effects on myocardial ischaemia in patients with stable ischaemic heart disease after treatment with ramipril for 6 months.

Authors:  Ronnie Willenheimer; Steen Juul-Möller; Lennart Forslund; Leif Erhardt
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

5.  Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.

Authors:  Marie Mide Michelsen; Anna Bay Rask; Elena Suhrs; Kristoffer Flintholm Raft; Nis Høst; Eva Prescott
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

Review 6.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis.

Authors:  Eva Lonn
Journal:  Curr Atheroscler Rep       Date:  2002-09       Impact factor: 5.967

Review 7.  Endothelial effects of antihypertensive treatment: focus on irbesartan.

Authors:  Roberto Negro
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.